KZIA
Kazia Therapeutics Ltd ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$136.55M
P/E Ratio
—
EPS
$-7.59
Beta
1.62
52W High
$17.40
52W Low
$3.05
50-Day MA
$8.34
200-Day MA
$8.13
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.82
PEG Ratio
1.01
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
Fundamentals
| Revenue (TTM) | $1.90M |
| Gross Profit (TTM) | $1.90M |
| EBITDA | $-17.84M |
| Operating Margin | -14641.00% |
| Return on Equity | -106.90% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.85 |
| Book Value | $2.84 |
| Price-to-Book | 4.11 |
| Price-to-Sales (TTM) | 71.92 |
| EV/Revenue | 2900.17 |
| EV/EBITDA | -0.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 312.40% |
| Shares Outstanding | $11.43M |
| Float | $3.91B |
| % Insiders | 14.91% |
| % Institutions | 34.29% |
Historical Volatility
HV 10-Day
85.41%
HV 20-Day
115.82%
HV 30-Day
105.32%
HV 60-Day
106.51%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($21.44 target)
1
Strong Buy1
BuyData last updated: 4/28/2026